Results 1 to 10 of about 231,717 (193)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

ESC Heart Failure
Aims Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics.
Francesco Cappelli, Pablo Garcia-Pavia, Thibaud Damy   +2 more
exaly   +8 more sources

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy [PDF]

Nature Communications, 2021
Transthyretin amyloid cardiomyopathy is a treatable but often unrecognized cause of heart failure. We derived and validated a machine learning model based on medical diagnostic codes that identifies heart failure patients at risk for wild-type ...
Ahsan Huda, Adam Castaño, Anindita Niyogi, Jennifer Schumacher, Michelle Stewart, Marianna Bruno, Mo Hu, Faraz S. Ahmad, Rahul C. Deo, Sanjiv J. Shah   +9 more
doaj   +2 more sources

Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene [PDF]

Stem Cell Research, 2023
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease caused by the abnormal production of misfolded TTR protein by liver cells, which is then released systemically.
Pilar Montero-Calle, María Flandes-Iparraguirre, Bernd Kuebler, Begoña Arán, Eduardo Larequi, Ilazki Anaut, Giulia Coppiello, Xabier L. Aranguren, Anna Veiga, Maria Teresa Basurte Elorz, Manuel García de Yébenes, Juan J. Gavira, Felipe Prósper, Olalla Iglesias-García, Manuel M. Mazo Vega   +14 more
doaj   +3 more sources

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Several imaging parameters and biomarkers provide diagnostic and prognostic information for wild‐type transthyretin amyloid cardiomyopathy.
Mami Morioka, Seiji Takashio, Naoya Nakashima, Masato Nishi, Akira Fujiyama, Kyoko Hirakawa, Shinsuke Hanatani, Hiroki Usuku, Eiichiro Yamamoto, Masafumi Kidoh, Seitaro Oda, Kenichi Matsushita, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +2 more sources

Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges

Journal of Public Health and Primary Care, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type
Sweety Sharma, Bhawna Sharma
doaj   +2 more sources

Systemic Oxalosis Mimicking Transthyretin Amyloid Cardiomyopathy [PDF]

JACC: Case Reports
Background: Technetium-99m pyrophosphate (Tc-99m PYP) scintigraphy is a noninvasive imaging modality in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), though false positive results may result in adverse clinical outcomes.
Bhavya Ancha, MD, Virginia Hahn, MD, Charles Steenbergen, Jr., MD, PhD, Cheng-Ying Ho, MD, PhD, Ahmad Kohsar, DO, Emily Brown, MGC, CGC, Mark Ranek, PhD, Claire Brookmeyer, MD, Michael Polydefkis, MD, Joban Vaishnav, MD   +9 more
doaj   +2 more sources

Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy [PDF]

JACC: Case Reports
Background: Left ventricular wall thickening may result from disease such as hypertrophic cardiomyopathy (HCM) or infiltrative cardiomyopathies such as transthyretin amyloidosis (ATTR).
Roxanne Coderre, MD, Gregorio Tersalvi, MD, Rosalyn O. Adigun, MD, Barry A. Boilson, MD, Daniel D. Borgeson, MD, Alfredo L. Clavell, MD, Ian C. Chang, MD, Angela Dispenzieri, MD, Martha Grogan, MD, Omar F. AbouEzzeddine, MDCM, MS   +9 more
doaj   +2 more sources

Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association
Background Although tafamidis treatment improves prognosis in patients with wild‐type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear.
Shinsuke Hanatani, Kenichi Tsujita, Seiji Takashio   +2 more
exaly   +3 more sources

AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods

Терапевтический архив, 2021
There are presented the literature data and a description of the clinical course of the disease in isolated/predominant cardiac amyloidosis. Amyloid cardiomyopathy is the most common phenocopy of hypertrophic cardiomyopathy.
Alexandra Ya. Gudkova, Sergei V. Lapekin, Tinatin G. Bezhanishvili, Maria A. Trukshina, Victoria G. Davydova, Aleksandr N. Krutikov, Aleksandr N. Kulikov, Anna A. Streltsova, Sofiia E. Andreeva, Roman V. Grozov, Anzhelika A. Poliakova, Anna A. Kostareva, Galina N. Salogub, Evgenii V. Shlyakhto   +13 more
doaj   +1 more source

A new era in treatment of cardiac amyloidosis: an overview of the Congress of cardiology

Лечащий Врач, 2022
Amyloidosis is a group of diseases characterized  by accumulation of a protein of a specific fibrillar structure in the interstitium of various organs and tissues.
I. E. Strelkova
doaj   +1 more source